Severity of Asthma Score Predicts Clinical Outcomes in Patients With Moderate to Severe Persistent Asthma

被引:46
|
作者
Eisner, Mark D. [1 ]
Yegin, Ashley [1 ]
Trzaskoma, Benjamin [1 ]
机构
[1] Genentech Inc, Prod Dev Inflammat & Resp, San Francisco, CA 94080 USA
关键词
TO-TREAT ASTHMA; BASE-LINE CHARACTERISTICS; RISK-FACTORS; ACTIVITY IMPAIRMENT; WORK DISABILITY; ADULT ASTHMA; VALIDITY; HOSPITALIZATION; PRODUCTIVITY; SPECIALISTS;
D O I
10.1378/chest.11-0020
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The severity of asthma (SOA) score is based on a validated disease-specific questionnaire that addresses frequency of asthma symptoms, use of systemic corticosteroids, use of other asthma medications, and history of hospitalization/intubation for asthma. SOA does not require measurements of pulmonary function. This study compared the ability of SOA to predict clinical outcomes in the EXCELS (Epidemiological Study of Xolair [omalizumab]: Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate to Severe Asthma) patient population vs three other asthma assessment tools. EXCELS is a large, ongoing, observational study of patients with moderate to severe persistent asthma and reactivity to perennial aeroallergens. Methods: Baseline scores for SOA, asthma control test (ACT), work productivity and impairment index-asthma (WPAI-A), and FEV(1) % To predicted were compared for their ability to predict five prespecified adverse clinical outcomes in asthma: serious adverse events (SAEs) reported as exacerbations, SAEs leading to hospitalizations, the incidence of unscheduled office visits, ED visits, and po or IV corticosteroid bursts related to asthma. Logistic regression analysis, area under receiver operating characteristic curves (AUCROCs), and classification and regression tree (CART) analysis were used to evaluate the ability of the four tools to predict adverse clinical outcomes using baseline and 1-year data from 2,878 patients enrolled in the non-omalizumab cohort of EXCELS. Results: SOA was the only assessment tool contributing significantly in all five statistical models of adverse clinical outcomes by logistic regression analysis (full model AUCROC range, 0.689-0.783). SOA appeared to be a stand-alone predictor for four of five outcomes (reduced model AUCROC range, 0.689-0.773). CART analysis showed that SOA had the greatest variable importance for all five outcomes. Conclusions: SOA score was a powerful predictor of adverse clinical outcomes in moderate to severe asthma, as evaluated by either logistic regression analysis or CART analysis.
引用
下载
收藏
页码:58 / 65
页数:8
相关论文
共 50 条
  • [21] Assessment of Clinical Asthma Score and Asthma Severity Score in Preschool Children with Recurrent Wheezing
    Ciftci, Nurdan
    Vezir, Emine
    Alioglu, Bulent
    ASTIM ALLERJI IMMUNOLOJI, 2021, 19 (03): : 136 - 141
  • [22] Itepekimab for Patients with moderate to severe Asthma
    Meinrenken, Susanne
    PNEUMOLOGIE, 2022, 76 (01): : 12 - 12
  • [23] The Composite Asthma Severity Index: A Tool for Assessing Impact of Omalizumab Treatment in Children with Moderate-to-Severe Persistent Allergic Asthma
    Szefler, Stanley J.
    Haselkorn, Tmirah
    Ortiz, Benjamin
    Trzaskoma, Benjamin L.
    Iqbal, Ahmar
    Busse, William W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB100 - AB100
  • [24] Asthma control and quality of life in patients with moderate or severe asthma
    Barros Pereira, Eanes Delgado
    de Matos Cavalcante, Antonio George
    Silva Pereira, Eduardo Nolla
    Lucas, Pedro
    Holanda, Marcelo Alcantara
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2011, 37 (06) : 705 - 711
  • [25] Effect Of Roflumilast On Asthma Control In Moderate and Severe Asthma Patients
    Beloglazov, V. A.
    Popenko, Yuri
    DuBuske, Lawrence M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB3 - AB3
  • [26] Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
    Hanania, Nicola A.
    Castro, Mario
    Bateman, Eric
    Pavord, Ian D.
    Papi, Alberto
    FitzGerald, J. Mark
    Maspero, Jorge F.
    Katelaris, Constance H.
    Singh, Dave
    Daizadeh, Nadia
    Altincatal, Arman
    Pandit-Abid, Nami
    Soler, Xavier
    Siddiqui, Shahid
    Laws, Elizabeth
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Lederer, David J.
    Hardin, Megan
    Deniz, Yamo
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 130 (02) : 206 - 214.e2
  • [27] Reasons for discontinuation of Omalizumab therapy in the treatment of patients with moderate to severe persistent asthma
    Sheinkopf, L. E.
    Rafi, A. W.
    Do, L. T.
    Klaustermeyer, W. B.
    Katz, R. M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S139 - S139
  • [28] Utility of Serum Environmental Allergen Testing in Patients with Moderate to Severe Persistent Asthma
    Arain, Zara
    Kanaley, Madeleine
    Fierstein, Jamie
    Boon, Kathy
    Bozen, Alexandria
    Fishbein, Joseph
    Gupta, Ruchi
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB130 - AB130
  • [29] Clinical and inflammatory phenotypic profile of the moderate and severe persistent asthma in a tertiary hospital of Barcelona
    Galvan, Blasco P.
    Soto-Retes, L.
    Mateus-Medina, E. F.
    Ramos, D.
    Plaza, V
    ALLERGY, 2020, 75 : 406 - 406
  • [30] Performance of a novel clinical score, the Pediatric Asthma Severity Score (PASS), in the evaluation of acute asthma
    Gorelick, MH
    Stevens, MW
    Schultz, TR
    Scribano, PV
    PEDIATRIC RESEARCH, 2002, 51 (04) : 212A - 212A